SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is experiencing extreme volatility, with the community actively debating whether it's a short squeeze or a pump and dump. The stock's low float and history of reverse splits are fueling speculation, with some comparing it to previous high-flying stocks like HKD and TGL. Traders are closely watching for offering news and momentum above key price levels, while others are suggesting it's overvalued and due for a correction.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

NFLX is trending amid speculation of acquiring Warner Bros. Discovery, potentially creating a streaming giant with HBO content; the community debates the deal's implications, regulatory hurdles, and whether it's a strategic win or overreach. Community sentiment seems mixed, with some anticipating a significant boost if the acquisition is approved, while others express concerns regarding regulatory hurdles and market saturation.

Treasure Global, Inc. engages in the provision of payment solutions. The firm created an online-to-offline (O2O) e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs. It operates through the ZCITY Platform and Customized Software Development Service segments. The company was founded by Kok Pin Tan on March 20, 2020 and is headquartered in New York, NY.

Treasure Global Inc

TREASURE GLOBAL INC

TGL is trending due to a recent reverse split and resulting small float, leading to high volatility and discussions of potential short squeezes. The community is comparing TGL to other high-flying stocks like $SMX, with some anticipating a similar explosive run. Bullish sentiment is fueled by the company's shift towards fintech and AI, with potential catalysts including new product rollouts and partnership announcements.

Wheeler Real Estate Investment Trust, Inc. engages in the acquisition, finance, development, lease, ownership, and management of retail properties. Its property portfolio includes income producing, strip centers, neighborhood, grocery-anchored, community, and free-standing retail properties. The company was founded on June 23, 2011 and is headquartered in Virginia Beach, VA.

Wheeler Real Estate Investment Trust Inc

WHLR is trending due to increased social media and community attention, with traders actively discussing a potential short squeeze and comparing it to recent runs of other low float stocks. The stock's high short interest and cost to borrow are key talking points, with some believing it has the potential for significant upward movement. However, caution is advised due to the company's history of reverse splits and volatile price action.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Traders are actively discussing Adobe's ($ADBE) recent performance, with some citing technical indicators suggesting a bullish trend, while others express frustration with the stock's inability to sustain gains. Community sentiment appears mixed amidst discussions around AI competition, potential undervaluation, and upcoming earnings. Chatter includes opinions on management, potential acquisitions, and speculation on future price movements.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending as natural gas prices have been volatile, with traders actively discussing potential entry points and swing trading strategies. Community members are weighing factors like weather forecasts, storage levels, and technical indicators to gauge short-term movements. Some traders express caution, citing the potential for price manipulation and the impact of contract rollovers.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending amid speculation of a short squeeze, fueled by investor Martin Shkreli's bullish stance and a $100 near-term price target. The community is actively discussing the company's potential in photonics and comparing it to recent high-flying stocks like $SMX. With high volume and rising interest, traders are closely watching for continued upward momentum.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery (WBD) is trending amid speculation of a potential acquisition by Netflix, sparking debates about the deal's value and regulatory hurdles. Community chatter revolves around competing bids from Paramount and Comcast, with some expressing concerns over potential market manipulation and the fairness of the bidding process. Discussions also include the potential impact on streaming competition and the future of WBD's assets.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne ($S) is trending following earnings, with community members noting the raised revenue forecast and discussing whether the stock is undervalued compared to its peers in the cybersecurity sector like Crowdstrike.  Some are focused on potential buyout scenarios and upcoming price target adjustments from analysts. There's also discussion around CFO departure and potential impact.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is trending as investors debate its valuation after Q3 earnings and revenue beat estimates. While subscription growth is fueling positive sentiment and multiple analysts upgraded the stock, some community members point to negative cash flow and strong resistance around the $90 mark. Discussions also include potential catalysts from AI and strategic partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Sciences Corp. (Anavex or the Company) (NASDAQ...

Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL)

Anavex Life Sciences (AVXL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Anavex Life Sciences' (AVXL) "Buy" Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued a "buy" rating and set a $24.00 price target on shares of Anavex Life Sciences in a research report on Wednesday...

Anavex Life Sciences (NASDAQ:AVXL) Posts Earnings Results, Beats Expectations By $0.02 EPS

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating...

<ul class="summary-bullets"><li>The company said its net loss for the three months through the end of September was $0.11 per share, down from a loss of $0.14 per share in the corresponding quarter of 2024.</li><li>The company is now seeking a re-examination of CHMP’s opinion on its Alzheimer’s drug, Blarcamesine.&nbsp;</li><li>It expects a cash runway of more than 3 years.</li></ul> Shares of Anavex Life Sciences Corp. (AVXL) jumped 10% on Monday afternoon after the company reported a lower-than-expected loss for the fourth quarter.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.anavex.com/post/anavex-life-sciences-reports-fiscal-2025-fourth-quarter-financial-results-and-provides-business-upd">said</a> that net loss in the three months through the end of September was $0.11 per share, down from a loss of $0.14 per share in the corresponding quarter of 2024, and lower than the loss of $0.15 per share expected by analysts, according to data from Fiscal AI.The company ended the quarter with cash and cash equivalents of $102.6 million. It now expects a cash runway of more than 3 years.<h2 class="st-heading-2">Blarcamesine’s Path Forward</h2>Anavex is focused on developing treatments for neurodegenerative disorders like Alzheimer’s. “There are currently an estimated 7.2 million people living with Alzheimer’s disease in the U.S. and 7 million in Europe, respectively. We continue to be focused on orally, targeted upstream medicines, particularly in the context of early Alzheimer’s disease,” said CEO Christopher U. Missling.Earlier this month, Anavex<a href="https://stocktwits.com/news-articles/markets/equity/avxl-shares-slump-pre-market-after-ema-committee-fails-to-recommend-approval-for-alzheimers-drug/cLPQ7tkRE4E"> said</a> that a European Medicines Agency (EMA) committee did not recommend approval of the company’s application for its Alzheimer’s drug, Blarcamesine. The Committee for Medicinal Products for Human Use provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug. The lack of a positive recommendation dampens the chances of EMA approval for the drug.The committee is expected to adopt a formal opinion on the application at its December meeting, the company said, while adding that it intends to request a re-examination of the committee’s opinion. The firm reiterated the course of action on Tuesday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AVXL stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user opined that they are “cautiously optimistic” about the stock’s future.<stembedurl>https://stocktwits.com/Filldagap/message/637414773</stembedurl>AVXL stock is down 68% this year and by 63% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/pmcb-stock-jumps-after-company-sells-stake-in-femasys/cL52o2lREgL">PMCB Stock Jumps 25% After Company Sells Stake In Femasys</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

 In this photo illustration, an Anavex Life Sciences Corp. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug

Anavex ended the quarter with cash and cash equivalents of $102.6 million.

Equity

Anavex ended the quarter with cash and cash equivalents of $102.6 million.


A Preview Of Anavex Life Sciences's Earnings

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

<ul class="summary-bullets"><li>The CHMP issued a negative trend vote but postponed its final decision to December.</li><li>Retail traders were divided, citing leadership concerns, cash pressure and subgroup data.</li><li>Some pointed to re-examination plans and potential FDA activity over the coming months.</li></ul>Anavex Life Sciences drew a wave of retail discussion over the weekend after the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)&nbsp;delayed its verdict on the biotech’s Alzheimer’s drug Blarcamesine until December.<a href="https://stocktwits.com/symbol/AVXL">Anavex shares</a> fell 36% on Friday,&nbsp;marking their worst single-day drop in over eight years, after the committee&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/avxl-shares-slump-pre-market-after-ema-committee-fails-to-recommend-approval-for-alzheimers-drug/cLPQ7tkRE4E">published a list of ten medicines</a> it backed at its latest meeting, and Blarcamesine was not among them. Anavex later confirmed it had received a negative trend vote following its oral explanation and noted that a formal opinion is expected in December. The company also stated that it plans to request a re-examination once the opinion is issued. The drug was not listed among withdrawn applications, leaving the procedure formally open heading into the next meeting.<h2 class="st-heading-2">Retail Reads Delay As Potentially Encouraging</h2>On Stocktwits, retail sentiment for Anavex was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:973/143;" src="https://news.stocktwits-cdn.com/avxl_ss_jpg_c386ff95ec.webp" alt="avxl ss.jpg" width="973" height="143"><figcaption>AVXL sentiment and message volume as of November 16 | Source: Stocktwits</figcaption></figure>Some retail traders pointed to the committee’s timing as noteworthy. One user said the delay until December was “actually a positive sign,” arguing that drugs facing immediate rejection typically receive a negative opinion in the same meeting. The user suggested the additional time may reflect internal scientific disagreement and the need to examine wild-type and biomarker data more closely.<stembedurl>https://stocktwits.com/old_salt/message/636396729</stembedurl>Another user focused on potential upcoming regulatory activity, saying, “Odds of finding out about an FDA application in the next 3 months is in the very likely. That will give credibility to the appeal. Should make things interesting.”<stembedurl>https://stocktwits.com/badprecog/message/636405849</stembedurl><h2 class="st-heading-2">Concerns About Leadership</h2>Other traders focused on the company’s strategy as Anavex navigates the re-examination path. One user argued that the company needed “a new leadership, a good communicator… someone credible and recognize in the financial community,”&nbsp;<stembedurl>https://stocktwits.com/Alex1710/message/636408135</stembedurl>The same user said Anavex faces “challenging time, cash is limited, sharks are all around,” and outlined potential approaches, including continuing with the re-examination while advancing 3-71 for schizophrenia. They added that if the EMA ultimately rejects the re-examination, the company could shift its focus away from Alzheimer’s and prioritize the schizophrenia program. In their view, pursuing another Alzheimer’s Phase 3 trial alone would raise the possibility of a reverse split.<stembedurl>https://stocktwits.com/Alex1710/message/636401995</stembedurl><stembedurl>https://stocktwits.com/Alex1710/message/636400703</stembedurl><h2 class="st-heading-2">Debate Over CHMP Language&nbsp;</h2>Some users examined the CHMP’s communication more closely. One trader described the negative-trend wording as unusually vague, noting that the range of committee support or opposition was unclear. They said the statement’s ambiguity left “all options open” and likened the process to “Cold War”-style parsing of official language.&nbsp;<stembedurl>https://stocktwits.com/Bio_Oko/message/636408015</stembedurl>The same user argued that the drug’s open-label extension results had demonstrated what they saw as strong scientific signals, saying the “odds ratio went into double digits territory” and suggesting that larger pharmaceutical companies would be aware of those outcomes.<stembedurl>https://stocktwits.com/Bio_Oko/message/636407204</stembedurl><h2 class="st-heading-2">Focus On Precision-Medicine Subgroup</h2>Another user emphasized the potential role of precision medicine in the review, saying approval becomes more plausible if the SIGMAR1 wild-type subgroup showed no disease progression, consistent clinical benefit, biomarker alignment and a mechanistically predictable response. They argued that these factors could give the EMA a basis for conditional approval.<stembedurl>https://stocktwits.com/tobeme100/message/636403386</stembedurl>Anavex’s stock has declined 66% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Anavex Retail Traders See Silver Lining In EMA Committee Postpones Alzheimer’s Drug Verdict: Delay 'Actually A Positive Sign'

The CHMP issued a negative trend vote but postponed its final decision to December.

Anavex Life Sciences (NASDAQ:AVXL) Reaches New 12-Month Low - Here's Why

Anavex Life Sciences (NASDAQ:AVXL) Reaches New 12-Month Low - Should You Sell...

Anavex Shares Fall 35% After Negative EU Trend Vote On Alzheimer's Drug

(RTTNews) - Anavex Life Sciences Corp. (AVXL) dropped 35.15% to $3.69, down $2.00, after regulatory updates revealed that the Committee for Medicinal Products for Human Use - CHMP issued a negative...

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

$SOFI

$RDDT

$CVNA

$MSTR

Which stock do you think gets added to the S&amp;P 500 in today’s rebalance?

Stocktwits

Which stock do you think gets added to the S&P 500 in today’s rebalance?

Current Price	$4.38
Prev Close	$4.45
Open	$4.43
Dividend Yield	0.00%
50-Day Moving Average	$7.12
Beta	1.60
Avg. Volume	4.27M
PE Ratio	-8.18

52-Week High	$14.44
52-Week Low	$2.86
Market Capitalization	$397.6M
EPS (Annual)	-$0.5438
Price to Book	4.07
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

AVXL
Anavex Life Sciences Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AVXL News

AVXLAnavex Life Sciences Corp